Mc Callion Orla
Algemeen Adviseur bij ULTIMOVACS ASA
Vermogen: - $ op 30-04-2024
Profiel
Mc Callion Orla is currently the Head of Regulatory Affairs & QA at Ultimovacs ASA since 2021.
Prior to this, he worked as the Director of Regulatory Affairs at OxThera AB from 2012 to 2021.
Dr. Orla holds a doctorate degree from Queen's University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ULTIMOVACS AS
-.--% | 31-12-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Mc Callion Orla
| Bedrijven | Functie | Begin |
|---|---|---|
| ULTIMOVACS ASA | Algemeen Adviseur | 01-10-2021 |
Eerdere bekende functies van Mc Callion Orla
| Bedrijven | Functie | Einde |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Algemeen Adviseur | 01-10-2021 |
Opleiding van Mc Callion Orla
| Queen's University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ULTIMOVACS ASA | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
